COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
04/12/2025
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding [...]
Microbix Announces Initiation of Normal Course Issuer Bid
04/12/2025
For Repurchase of up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ) (“Microbix” or the “Company”), a [...]
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery
04/12/2025
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio , a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea , a leading global contract research [...]
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
04/12/2025
Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026 Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the [...]
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
04/12/2025
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical data in global [...]
Merakris Therapeutics Announces Completion of Type C Meeting with FDA – Alignment on MTX-001 Biologic Drug Development Pathway
04/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a clinical-stage biopharmaceutical company focused on advancing innovative biologic drug therapies for chronic wounds, announced [...]
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
04/12/2025
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China Collaboration designed to accelerate and expand the [...]
Press Release: Sanofi completes acquisition of Vicebio
04/12/2025
Sanofi completes acquisition of Vicebio Paris, December 4, 2025 . Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”) . This acquisition brings an early-stage combination vaccine candidate for [...]
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
04/12/2025
Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025 . Sanofi annonce aujourd’hui la finalisation de l’acquistion de Vicebio Ltd (« Vicebio ») . Cette acquisition apporte à Sanofi un candidat-vaccin [...]
DOGP Moves to Nearly Double DOG Token Holdings Through Strategic Agreement
04/12/2025
“Expanding Participation in a Digital Ecosystem With Real-World Utility” Mesquite, NV, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Mesquite, NV December 4, 2025 — Dogecoin Cash, Inc. (OTCQB: DOGP) today announced that its [...]
Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing
04/12/2025
San Diego, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Sapu Nano today announced new pharmacokinetic (PK) and tissue-distribution results demonstrating that Sapu003 , the company’s intravenous (IV) Deciparticle ™ [...]
Laigo Bio raises €11.5 million in seed financing to advance its SureTAC™ targeted protein degradation candidates in oncology and auto-immunity
04/12/2025
Financing co-led by Kurma Partners and Curie Capital, includes strong line-up of European investors Matthew Baker appointed as CEO Laigo Bio’s SureTAC™ membrane protein degradation technology targets key signaling [...]
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
04/12/2025
Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment [...]
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update
04/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]
Changes to Tecan’s Board of Directors proposed to shareholders at the upcoming Annual General Meeting 2026
04/12/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, December 4, 2025 – Tecan Group Ltd. (SIX Swiss Exchange: TECN) today announced that the Board of Directors [...]
Bestselling Author and Entrepreneur Dr. Reza Zahedi Expands into U.S. Market, Aiming to Build a Leading Real Estate and Media Portfolio
04/12/2025
Leadtainment founder and USA Today bestselling author announces bold U.S. expansion strategy, aiming to build a multi-million-dollar portfolio and deepen ties with key brokers, investors, and media partners. Photo [...]
The Hemp Doctor Introduces THCA Flower Subscription Box — Monthly Curated Rotating Strains, Pre-Rolls & Extras
04/12/2025
MOORESVILLE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, one of America’s leading hemp brands, announces the launch of its Fresh Bloom THCA Flower Subscription Box —delivering a curated monthly lineup of [...]
Hapbee Appoints Hasan Shahid to Board of Directors to Strengthen Capital Markets & Strategic Growth Capabilities
04/12/2025
Seasoned technologist, investor, and capital markets leader joins Hapbee’s Board VANCOUVER, British Columbia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB ; OTCQB: HAPBF ; FWB: HA1 ) (“ Hapbee [...]
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
04/12/2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of peripheral nerve function [...]

Pages